Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 2697-2704

  Skvara, Hans ^a   Thallinger, Christiane ^b   Wacheck, Volker ^b   Monia, Brett P ^c   Pehamberger, Hubert ^b,e   Jansen, Burkhard ^b,d   Selzer, Edgar ^a,b,e  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c ISIS PHARMACEUTICALS   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Center of Excellence for Clinical and Experimental Oncology (CLEXO)   (Austria)

Author keywords

Antisense oligonucleotides; Apoptosis; Bcl 2; Ionizing radiation; Mcl 1; Melanoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IONIZING RADIATION; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIATION RESPONSE; RADIOSENSITIVITY; WESTERN BLOTTING;

APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; HUMANS; MELANOMA; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION TOLERANCE; TRANSFECTION;

EID: 22944436158     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
2. Oltvai ZN and Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes. Cell 79: 189-192, 1994.
3. Fujise K, Zhang D, Liu J and Yeh ET: Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. J Biol Chem 275: 39458-39465, 2000.
4. Li L, Story M and Legerski RJ: Cellular responses to ionizing radiation damage. Int J Radiat Oncol Biol Phys 49: 1157-1162, 2001.
5. Craig RW: MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16: 444-454, 2002.
6. Kozopas KM, Yang T, Buchan HL, Zhou P and Craig RW: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to Bcl-2. Proc Natl Acad Sci USA 90: 3516-3520, 1993.
7. Yang T, Kozopas KM and Craig RW: The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 128: 1173-1184, 1995.
8. Krajewski S, Bodrug S, Krajewska M et al: Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 146: 1309-1319, 1995.
9. Selzer E, Schlagbauer-Wadl H, Okamoto I, Pehamberger H, Potter R and Jansen B: Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 8: 197-203, 1998.
10. Rogers S, Wells R and Rechsteiner M: Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 234: 364-368, 1986.
11. Jansen B and Zangemeister-Wittke U: Antisense therapy for cancer - the time of truth. Lancet Oncol 3: 672-683, 2002.
12. Monia BP, Holmlund J and Dorr FA: Antisense approaches for the treatment of cancer. Cancer Invest 18: 635-650, 2000.
13. Thallinger C, Wolschek MF, Wacheck V et al: Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 120: 1081-1086, 2003.
14. Zangemeister-Wittke U and Ziegler A: Bcl-2 antisense therapy for cancer: the art of persuading tumour cells to commit suicide. Apoptosis 3: 67-74, 1998.
15. Gautschi O, Tschopp S, Olie RA et al: Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 93: 463-471, 2001.
16. Jansen B, Wacheck V, Heere-Ress E et al: Chemosensitisation of malignant melanoma by Bcl-2 antisense therapy. Lancet 356: 1728-1733, 2000.
17. Webb A, Cunningham D, Cotter F et al: Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349: 1137-1141, 1997.
18. Wacheck V, Heere-Ress E, Halaschek-Wiener J et al: Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med 79: 587-593, 2001.
19. Heere-Ress E, Thallinger C, Lucas T et al: Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer 99: 29-34, 2002.
20. Olie RA, Hafner C, Kuttel R et al: Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol 118: 505-512, 2002.
21. Thallinger C, Wolschek MF, Wacheck V et al: Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 120: 1081-1086, 2003.
22. Jansen B, Schlagbauer-Wadl H, Brown BD et al: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4: 232-234, 1998.
23. Moulding DA, Quayle JA, Hart CA and Edwards SW: Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival. Blood 92: 2495-2502, 1998.
24. Zhou P, Qian L, Kozopas KM and Craig RW: Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89: 630-643, 1997.
25. Leuenroth SJ, Grutkoski PS, Ayala A and Simms HH: The loss of Mcl-1 expression in human polymorphonuclear leukocytes promotes apoptosis. J Leukoc Biol 68: 158-166, 2000.
26. Moulding DA, Giles RV, Spiller DG, White MR, Tidd DM and Edwards SW: Apoptosis is rapidly triggered by antisense depletion of Mcl-1 in differentiating U937 cells. Blood 96: 1756-1763, 2000.
27. Leuenroth SJ, Grutkoski PS, Ayala A and Simms HH: The loss of Mcl-1 expression in human polymorphonuclear leukocytes promotes apoptosis. J Leukoc Biol 68: 158-166, 2000.
28. Zhang B, Gojo I and Fenton RG: Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99: 1885-1893, 2002.
29. Thallinger C, Markus F, Wolschek M et al: Mcl-1 is a novel target in human sarcoma: synergistic inhibition of human sarcoma by a combination of Mcl-1 antisense oligonucleotides with low-dose cyclophosphamide in SCID mice. Clin Cancer Res 10: 4185-4191, 2004.
30. Tang L, Tron VA, Reed JC et al: Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 4: 1865-1871, 1998.
31. Kyprianou N, King ED, Bradbury D and Rhee JG: Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70: 341-348, 1997.
32. Breton C, Story MD and Meyn RE: Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide. Anticancer Drugs 9: 751-757, 1998.
33. Yin DX and Schimke RT: Bcl-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 55: 4922-4928, 1995.
34. Held KD: Radiation-induced apoptosis and its relationship to loss of clonogenic survival. Apoptosis 2: 265-282, 1997.
35. Wacheck V, Selzer E, Gunsberg P et al: Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells. Br J Cancer 89: 1352-1357, 2003.